Innovent Biologics (Hangzhou) Co., Ltd (HKG: 1801, OTCMKTS: IVBXF), a biopharmaceutical company based in China, has announced the successful initiation of a Phase I clinical trial for its proprietary IBR822 cell injection solution at Zhejiang Cancer Hospital. The trial, led by Professor Song Zhengbo from Zhejiang Cancer Hospital, is conducted in collaboration with nationally recognized clinical research centers including the First Hospital of Jiaxing City and Fuyang Tumor Hospital.
The kick-off meeting was attended by key figures such as Professor Song Zhengbo, Director of the Phase I Clinical Trial Ward at Zhejiang Cancer Hospital, Teacher Hong Dan, Deputy Director of the GCP Center, and clinical research teams from relevant departments. The Inventive Biologics clinical medical team and the CRO Kunling Enterprise Management and Operations team were also present. The meeting, chaired by Professor Song, provided a detailed introduction to the implementation process and details of the Phase I clinical trial protocol for IBR822 cell injection solution in solid tumors. It included comprehensive discussions and analyses of the key points and challenges of the trial, proposing many practical suggestions and measures to ensure the high-quality conduct of the trial.
IBR822 cell injection solution is a globally pioneering CAR-raNK product developed by Innovent using its proprietary intellectual property rights. It is a non-viral, non-genetically modified NK cell product capable of specifically targeting the Trop2 antigen and killing tumor cells. Preclinical studies have shown significant cytotoxic effects of IBR822 cell injection solution on various tumor cell lines. On April 19, 2024, IBR822 cell injection solution received implicit approval from the National Medical Products Administration (NMPA) for clinical trials, marking a significant step forward for China in the field of cell therapy. -Fineline Info & Tech
